Cargando…
Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management
BACKGROUND: Malignant struma ovarii is an ovarian teratoma containing at least 50% thyroid tissue which has the potential to metastasize and produce thyroid hormone. Given its rarity, management strategies are not well-established. We report a case of metastatic malignant struma ovarii discovered du...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006564/ https://www.ncbi.nlm.nih.gov/pubmed/29946481 http://dx.doi.org/10.1186/s40842-018-0064-5 |
_version_ | 1783332860367732736 |
---|---|
author | Lager, Corey J. Koenig, Ronald J. Lieberman, Richard W. Avram, Anca M. |
author_facet | Lager, Corey J. Koenig, Ronald J. Lieberman, Richard W. Avram, Anca M. |
author_sort | Lager, Corey J. |
collection | PubMed |
description | BACKGROUND: Malignant struma ovarii is an ovarian teratoma containing at least 50% thyroid tissue which has the potential to metastasize and produce thyroid hormone. Given its rarity, management strategies are not well-established. We report a case of metastatic malignant struma ovarii discovered during pregnancy with lessons for evaluation and management. CASE PRESENTATION: A 30-year-old woman who was two months pregnant was discovered to have struma ovarii with over half of the struma comprised of papillary thyroid cancer. Following tumor resection, delivery, and thyroidectomy, she underwent evaluation with stimulated thyroglobulin testing and diagnostic staging sodium iodide-131 scan (I-131), which revealed the presence of skeletal metastases. Following administration of 320 mCi I-131, post-therapy scan also showed miliary pulmonary metastases with improved ability to localize the bony and pulmonary metastases with concurrent SPECT/CT imaging. A second dosimetry-guided I-131 therapy resulted in complete resolution of pulmonary metastases; however, small foci of residual bone disease persisted. Post-therapy scans demonstrated additional findings not shown on diagnostic I-131 scans obtained prior to both her initial and second I-131 therapy. CONCLUSIONS: SPECT/CT provides accurate anatomic correlation and localization of metastatic foci and can serve as a baseline study to assess interval response to treatment. Post-therapy scans should always be obtained when I-131 treatment is administered, as additional findings may be revealed versus low dose I-131 activity diagnostic scans. This patient had a high metastatic burden that would not have been discovered in a timely fashion with the conservative approach advocated by others. Thyroidectomy followed by a diagnostic staging radioiodine scan and a stimulated thyroglobulin level should be considered in patients with malignant struma ovarii for guiding therapeutic I-131 administration as metastatic risk is difficult to predict based on histopathologic examination. |
format | Online Article Text |
id | pubmed-6006564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60065642018-06-26 Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management Lager, Corey J. Koenig, Ronald J. Lieberman, Richard W. Avram, Anca M. Clin Diabetes Endocrinol Case Report BACKGROUND: Malignant struma ovarii is an ovarian teratoma containing at least 50% thyroid tissue which has the potential to metastasize and produce thyroid hormone. Given its rarity, management strategies are not well-established. We report a case of metastatic malignant struma ovarii discovered during pregnancy with lessons for evaluation and management. CASE PRESENTATION: A 30-year-old woman who was two months pregnant was discovered to have struma ovarii with over half of the struma comprised of papillary thyroid cancer. Following tumor resection, delivery, and thyroidectomy, she underwent evaluation with stimulated thyroglobulin testing and diagnostic staging sodium iodide-131 scan (I-131), which revealed the presence of skeletal metastases. Following administration of 320 mCi I-131, post-therapy scan also showed miliary pulmonary metastases with improved ability to localize the bony and pulmonary metastases with concurrent SPECT/CT imaging. A second dosimetry-guided I-131 therapy resulted in complete resolution of pulmonary metastases; however, small foci of residual bone disease persisted. Post-therapy scans demonstrated additional findings not shown on diagnostic I-131 scans obtained prior to both her initial and second I-131 therapy. CONCLUSIONS: SPECT/CT provides accurate anatomic correlation and localization of metastatic foci and can serve as a baseline study to assess interval response to treatment. Post-therapy scans should always be obtained when I-131 treatment is administered, as additional findings may be revealed versus low dose I-131 activity diagnostic scans. This patient had a high metastatic burden that would not have been discovered in a timely fashion with the conservative approach advocated by others. Thyroidectomy followed by a diagnostic staging radioiodine scan and a stimulated thyroglobulin level should be considered in patients with malignant struma ovarii for guiding therapeutic I-131 administration as metastatic risk is difficult to predict based on histopathologic examination. BioMed Central 2018-06-19 /pmc/articles/PMC6006564/ /pubmed/29946481 http://dx.doi.org/10.1186/s40842-018-0064-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Lager, Corey J. Koenig, Ronald J. Lieberman, Richard W. Avram, Anca M. Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management |
title | Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management |
title_full | Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management |
title_fullStr | Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management |
title_full_unstemmed | Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management |
title_short | Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management |
title_sort | rare clinical entity: metastatic malignant struma ovarii diagnosed during pregnancy – lessons for management |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006564/ https://www.ncbi.nlm.nih.gov/pubmed/29946481 http://dx.doi.org/10.1186/s40842-018-0064-5 |
work_keys_str_mv | AT lagercoreyj rareclinicalentitymetastaticmalignantstrumaovariidiagnosedduringpregnancylessonsformanagement AT koenigronaldj rareclinicalentitymetastaticmalignantstrumaovariidiagnosedduringpregnancylessonsformanagement AT liebermanrichardw rareclinicalentitymetastaticmalignantstrumaovariidiagnosedduringpregnancylessonsformanagement AT avramancam rareclinicalentitymetastaticmalignantstrumaovariidiagnosedduringpregnancylessonsformanagement |